Ignite Creation Date:
2024-05-06 @ 4:26 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04987320
Status:
COMPLETED
Last Update Posted:
2023-09-25
First Post:
2021-07-26
Brief Title:
A Study to Evaluate the Pharmacokinetics Pharmacodynamics Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoproteina
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open-label Single-dose Study to Evaluate the Pharmacokinetics Pharmacodynamics Safety and Tolerability of Olpasiran in Chinese Subjects With Elevated Serum Lipoproteina
Status:
COMPLETED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this study is to evaluate the pharmacokinetics PK of a single dose of Olpasiran in Chinese participants with elevated serum lipoproteina Lpa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None